West Oak Capital LLC Has $137,000 Position in Stryker Co. (NYSE:SYK)

West Oak Capital LLC grew its holdings in Stryker Co. (NYSE:SYK) by 26.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 380 shares of the medical technology company’s stock after buying an additional 80 shares during the quarter. West Oak Capital LLC’s holdings in Stryker were worth $137,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Dunhill Financial LLC increased its holdings in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Centennial Bank AR increased its stake in shares of Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after buying an additional 48 shares during the period. Darwin Wealth Management LLC bought a new stake in shares of Stryker during the third quarter worth $36,000. HBW Advisory Services LLC acquired a new position in shares of Stryker during the third quarter valued at $42,000. Finally, Hara Capital LLC bought a new position in Stryker in the third quarter valued at about $42,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.50% of the stock is currently owned by insiders.

Stryker Stock Performance

SYK stock traded up $1.94 during trading hours on Friday, reaching $366.04. The stock had a trading volume of 1,313,772 shares, compared to its average volume of 1,285,595. The stock has a 50-day simple moving average of $375.42 and a 200 day simple moving average of $357.51. Stryker Co. has a fifty-two week low of $306.10 and a fifty-two week high of $398.20. The stock has a market capitalization of $139.54 billion, a PE ratio of 39.23, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company posted $2.46 earnings per share. Analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker’s payout ratio is presently 36.01%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. BTIG Research upped their target price on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Royal Bank of Canada restated an “outperform” rating and issued a $425.00 price objective on shares of Stryker in a report on Tuesday. UBS Group upped their target price on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Citigroup raised their target price on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Barclays upped their price target on Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $405.80.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.